LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

LLY

735.02

+1.26%↑

JNJ

177.01

-0.32%↓

ABBV

210.01

+0.49%↑

UNH

330.34

+3.53%↑

NVO

53.02

-2.79%↓

Search

Amphastar Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

29.1 1.57

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

28.69

Max

29.4

Pagrindiniai rodikliai

By Trading Economics

Pajamos

5.7M

31M

Pardavimai

3.9M

174M

P/E

Sektoriaus vid.

11.468

35.733

Pelno marža

17.791

Darbuotojai

2,028

EBITDA

9.5M

62M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+8.77% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

415M

1.4B

Ankstesnė atidarymo kaina

27.53

Ankstesnė uždarymo kaina

29.1

Naujienos nuotaikos

By Acuity

50%

50%

173 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

Amphastar Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-08 23:59; UTC

Įsigijimai, susijungimai, perėmimai

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

2025-09-08 22:02; UTC

Pagrindinės rinkos jėgos

Microsoft Signs $17.4 Billion AI Deal With Nebius

2025-09-08 17:01; UTC

Pagrindinės rinkos jėgos

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

2025-09-08 17:01; UTC

Pagrindinės rinkos jėgos

Tron Shares Rise After New Investment From Bravemorning

2025-09-08 16:14; UTC

Pagrindinės rinkos jėgos

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

2025-09-08 16:13; UTC

Pagrindinės rinkos jėgos

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

2025-09-08 23:12; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-08 23:12; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-08 23:12; UTC

Rinkos pokalbiai

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

2025-09-08 22:56; UTC

Rinkos pokalbiai

Worst May Be Over for New Zealand Retailers -- Market Talk

2025-09-08 22:23; UTC

Rinkos pokalbiai

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

2025-09-08 21:51; UTC

Rinkos pokalbiai

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

2025-09-08 21:47; UTC

Pagrindinės rinkos jėgos

Microsoft Signs $17.4B AI Deal With Nebius

2025-09-08 21:33; UTC

Įsigijimai, susijungimai, perėmimai

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

2025-09-08 21:20; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

2025-09-08 21:19; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

2025-09-08 21:18; UTC

Įsigijimai, susijungimai, perėmimai

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

2025-09-08 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-09-08 19:33; UTC

Rinkos pokalbiai

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

2025-09-08 19:22; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Settle Higher -- Market Talk

2025-09-08 19:02; UTC

Rinkos pokalbiai

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

2025-09-08 18:24; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-08 18:24; UTC

Rinkos pokalbiai

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

2025-09-08 17:29; UTC

Rinkos pokalbiai

Mexican Inflation Seen Little Changed in August -- Market Talk

2025-09-08 16:59; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

2025-09-08 16:36; UTC

Rinkos pokalbiai

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

2025-09-08 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-09-08 16:16; UTC

Uždarbis

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

2025-09-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-09-08 16:04; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Amphastar Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

8.77% į viršų

12 mėnesių prognozė

Vidutinis 32 USD  8.77%

Aukščiausias 36 USD

Žemiausias 25 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Amphastar Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

2

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

23.91 / 25.04Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bullish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

173 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
help-icon Live chat